Cellectar Biosciences Stock Price, News & Analysis (NASDAQ:CLRB) $2.55 0.00 (0.00%) (As of 12/6/2023 ET) Add Compare Share Share Today's Range$2.45▼$2.6250-Day Range$1.94▼$2.9152-Week Range$1.25▼$3.15Volume110,925 shsAverage Volume232,270 shsMarket Capitalization$31.34 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Cellectar Biosciences MarketRank™ Stock AnalysisAnalyst Rating0.00 Rating ScoreUpside/Downside292.2% Upside$10.00 Price TargetShort InterestHealthy6.87% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.85) to ($2.30) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.32 out of 5 starsMedical Sector888th out of 957 stocksPharmaceutical Preparations Industry378th out of 399 stocks 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, Cellectar Biosciences has a forecasted upside of 292.2% from its current price of $2.55.Amount of Analyst CoverageCellectar Biosciences has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted6.87% of the float of Cellectar Biosciences has been sold short.Short Interest Ratio / Days to CoverCellectar Biosciences has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cellectar Biosciences has recently decreased by 7.16%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCellectar Biosciences does not currently pay a dividend.Dividend GrowthCellectar Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CLRB. Previous Next 0.6 News and Social Media Coverage News SentimentCellectar Biosciences has a news sentiment score of -0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Cellectar Biosciences this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for CLRB on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cellectar Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.60% of the stock of Cellectar Biosciences is held by insiders.Percentage Held by InstitutionsOnly 16.41% of the stock of Cellectar Biosciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cellectar Biosciences are expected to grow in the coming year, from ($2.85) to ($2.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cellectar Biosciences is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cellectar Biosciences is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCellectar Biosciences has a P/B Ratio of 1.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cellectar Biosciences Stock (NASDAQ:CLRB)Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.Read More CLRB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLRB Stock News HeadlinesDecember 5, 2023 | finance.yahoo.comCellectar Biosciences to Present at the Targeted Radiopharmaceuticals Summit EuropeNovember 23, 2023 | finance.yahoo.comHere's Why We're A Bit Worried About Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn SituationDecember 7, 2023 | Financial Alphas (Ad)Lithium Discovery So BIG You Can't Miss it, Even From SpaceWith the green energy transition well underway, lithium demand is rapidly outpacing projected supply. While companies frantically search for new sources of this critical metal, one small company is sitting on a massive claim in North America - So big in fact that it can clearly be seen from space!November 4, 2023 | markets.businessinsider.comBuy Rating on Cellectar Biosciences: Promising Clinical Study, Fast Track Designation and Strong Financial PositionNovember 4, 2023 | finance.yahoo.comCellectar Biosciences, Inc. (NASDAQ:CLRB) Q3 2023 Earnings Call TranscriptNovember 2, 2023 | msn.comCellectar Biosciences Q3 2023 Earnings PreviewNovember 2, 2023 | finance.yahoo.comCellectar to Release Top-line Data from WM Pivotal Trial During the JP Morgan Healthcare Conference the Week of January 8, 2024October 25, 2023 | finance.yahoo.comCellectar Biosciences Partners with Florida Cancer Specialists & Research Institute to Support the Treatment of Waldenstrom's Macroglobulinemia in the Community SettingDecember 7, 2023 | Edge On The Street (Ad)Americans Now Favor Gold Over Stocks as an Investment VehicleAmericans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges. October 24, 2023 | finance.yahoo.comCellectar Biosciences to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 2, 2023October 17, 2023 | finance.yahoo.comCellectar Biosciences Expands Commercialization Leadership Team Ahead of Pivotal Data for Iopofosine I-131 in Waldenstrom's MacroglobulinemiaOctober 7, 2023 | seekingalpha.comCellectar Biosciences files to sell 34.5M shares for holdersOctober 2, 2023 | marketwatch.comCellectar Biosciences Shares Rise 10% After Being Granted Four PatentsOctober 2, 2023 | finance.yahoo.comCellectar Biosciences Expands Global Intellectual Property Portfolio with Four Patent GrantsSeptember 18, 2023 | finance.yahoo.comCellectar Biosciences Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom’s MacroglobulinemiaSeptember 18, 2023 | benzinga.comNano-Cap Medical Technology Watchlist (ORHB, BBLG, CLRB, MOVE)September 11, 2023 | benzinga.comCellectar Biosciences Announces Closing of up to Approximately $103 Million Private Placement FinancingSeptember 5, 2023 | marketwatch.comCellectar Biosciences Shares Rise 18% After Private Placement FinancingSeptember 5, 2023 | msn.comCellectar Biosciences announces up to ~$103M private placement financingSeptember 5, 2023 | finance.yahoo.comCellectar Biosciences Announces up to Approximately $103 Million Private Placement FinancingAugust 14, 2023 | finanznachrichten.deCellectar Biosciences: Cellectar Reports Financial Results for Second Quarter 2023 and Provides a Corporate UpdateAugust 14, 2023 | finance.yahoo.comCellectar Reports Financial Results for Second Quarter 2023 and Provides a Corporate UpdateJune 28, 2023 | finance.yahoo.comCellectar Biosciences Highlights Promising Interim Data from Its Ongoing Study of Iopofosine I 131 in Multiple Myeloma in an Oral Presentation at the SNMMI Annual MeetingJune 27, 2023 | finance.yahoo.comCLRB - Cellectar Biosciences, Inc.June 12, 2023 | finance.yahoo.comCellectar Provides a Research and Development Program SummaryMay 6, 2023 | morningstar.comUPDATE — Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate UpdateMay 6, 2023 | seekingalpha.comCellectar Biosciences GAAP EPS of -$0.76See More Headlines Receive CLRB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cellectar Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2021Today12/06/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/14/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CLRB CUSIPN/A CIK1279704 Webwww.cellectar.com Phone(608) 441-8120Fax608-441-8121Employees15Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+292.2%Consensus Rating Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)($3.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,600,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-3,821.29% Return on Assets-207.04% Debt Debt-to-Equity RatioN/A Current Ratio1.22 Quick Ratio1.22 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.51 per share Price / Book1.69Miscellaneous Outstanding Shares12,290,000Free Float11,723,000Market Cap$31.34 million OptionableNot Optionable Beta1.10 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. James V. Caruso (Age 64)President, CEO & Director Comp: $846.48kMr. Chad J. Kolean CPA (Age 59)VP, CFO & Secretary Comp: $453.22kMr. Jarrod Longcor (Age 50)Chief Operating Officer Comp: $625.32kMr. Darrell Shane Lea (Age 50)Chief Commercial Officer Dr. Andrei Shustov M.D. (Age 52)Senior Vice President of Medical Key CompetitorsEledon PharmaceuticalsNASDAQ:ELDNHomology MedicinesNASDAQ:FIXXGain TherapeuticsNASDAQ:GANXNeoleukin TherapeuticsNASDAQ:NLTXvTv TherapeuticsNASDAQ:VTVTView All CompetitorsInstitutional OwnershipWorth Venture Partners LLCSold 34,386 shares on 11/15/2023Ownership: 2.808%Acuta Capital Partners LLCBought 121,300 shares on 11/15/2023Ownership: 1.220%AIGH Capital Management LLCSold 135,686 shares on 11/13/2023Ownership: 6.816%View All Institutional Transactions CLRB Stock Analysis - Frequently Asked Questions What is Cellectar Biosciences' stock price target for 2024? 0 Wall Street research analysts have issued 12-month price targets for Cellectar Biosciences' shares. Their CLRB share price targets range from $10.00 to $10.00. On average, they anticipate the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 292.2% from the stock's current price. View analysts price targets for CLRB or view top-rated stocks among Wall Street analysts. How have CLRB shares performed in 2023? Cellectar Biosciences' stock was trading at $1.71 at the start of the year. Since then, CLRB shares have increased by 49.1% and is now trading at $2.55. View the best growth stocks for 2023 here. Are investors shorting Cellectar Biosciences? Cellectar Biosciences saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 800,100 shares, a decline of 7.2% from the October 31st total of 861,800 shares. Based on an average trading volume of 708,100 shares, the short-interest ratio is currently 1.1 days. Currently, 6.9% of the company's shares are sold short. View Cellectar Biosciences' Short Interest. When is Cellectar Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024. View our CLRB earnings forecast. How were Cellectar Biosciences' earnings last quarter? Cellectar Biosciences, Inc. (NASDAQ:CLRB) released its quarterly earnings data on Sunday, November, 7th. The biopharmaceutical company reported ($1.00) earnings per share for the quarter, beating analysts' consensus estimates of ($1.10) by $0.10. When did Cellectar Biosciences' stock split? Cellectar Biosciences shares reverse split on the morning of Friday, July 22nd 2022. The 1-10 reverse split was announced on Friday, July 22nd 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 22nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Cellectar Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectar Biosciences investors own include Hudbay Minerals (HBM), Zynga (ZNGA), Quantum (QTM), Baytex Energy (BTE), Sherritt International (S), Bombardier (BDRBF), Bombardier, Inc. Class B (BBD.B), Bonavista Energy Co. (BNP.TO) (BNP) and Hudbay Minerals (HBM). Who are Cellectar Biosciences' major shareholders? Cellectar Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include AIGH Capital Management LLC (6.82%), Worth Venture Partners LLC (2.81%) and Acuta Capital Partners LLC (1.22%). Insiders that own company stock include Dov Elefant, James V Caruso and Jarrod Longcor. View institutional ownership trends. How do I buy shares of Cellectar Biosciences? Shares of CLRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:CLRB) was last updated on 12/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectar Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.